RADprecise
Research type
Research Study
Full title
RADprecise – Personalized radiotherapy: incorporating cellular response to irradiation in personalized treatment planning to minimize radiation toxicity
IRAS ID
276520
Contact name
Christopher J Talbot
Contact email
Sponsor organisation
University of Leicester
Clinicaltrials.gov Identifier
DRKS00020290, German Clinical Trial Registry (DRKS)
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
Approximately half of all cancer patients receive radiotherapy as part of their cancer treatment. The dose of radiation is usually limited because of the risk of damaging normal tissues and organs that surround the tumour. Patients vary in their sensitivity to radiation, yet up to a quarter of patients may experience noticeable side-effects.
In recent years, researchers have developed predictive models and biological tests to try to identify those patients who are very sensitive before the start of radiation treatment. Some of this research has been carried out using samples from patients recruited into the international REQUITE observational study. To date, this has been the largest study of its kind, looking at patients receiving radiotherapy for breast, lung or prostate cancer in several European countries and the US.
However, there is currently no test or predictive model suitable for use in the clinic, so radiation doses for all patients remain limited by the risk of side-effects in the most sensitive patients. The RADprecise study is designed to follow-up breast and prostate cancer patients enrolled in the REQUITE study between 2014-16 for 3 years and beyond to collect more information, blood and bio-samples to allow researches to test models and biological tests for future use. In particular, we are looking at long-term (late) side-effects, which are important to quality-of-life, such as scarring, pain, problems passing urine and getting an erection. If we are successful, then in future we could identify the ‘radiosensitive’ patients before the start of their radiotherapy and allow us to personalise treatment to minimise these side-effects.
REC name
North West - Greater Manchester West Research Ethics Committee
REC reference
20/NW/0360
Date of REC Opinion
14 Sep 2020
REC opinion
Favourable Opinion